Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trialFei Ma, Binghe Xu, Zhongsheng Tong et al.|BMJ|2023Cited by 82
Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trialMin Yan, Fangzhou Xia, Quchang Ouyang et al.|EClinicalMedicine|2024Cited by 10